Atopic dermatitis

Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data

**Background:** Dupilumab is the first biologic registered for the treatment of moderate-to-severe atopic dermatitis (AD) and efficacy was shown in phase III clinical trials (primary outcome at week 16 was reached in 38% of patients). Currently, …